Nuwellis GAAP EPS of -$5.81, revenue of $2.21M

Nuwellis reported Q3 GAAP EPS of -$5.81 and revenue of $2.21M, down 0.5% year-over-year. Net sales increased 12% sequentially and 13% year-to-date, driven by U.S. circuit and console sales growth, according to the company.

Original reporting
Published Nov 12, 2026, 1:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NUWE
Bearish
medium confidence
Mentioned
$NUWE
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$NUWEBearishLow
01

Why it matters

The earnings miss is likely to trigger short‑term selling pressure, though the 12% sequential sales increase could provide a modest upside narrative.

02

Market read

Micro‑cap earnings release with negative EPS; limited broader market effect.

03

What to watch

Potential upside from U.S. circuit and console sales growth not fully reflected in the headline numbers.

Relevance 6/10Novelty 8/10Timing: after-hours release today

Background

Nuwellis Inc. (NUWE) reported its Q3 2026 results, showing a GAAP loss per share of $5.81 and revenue essentially flat year‑over‑year at $2.21 million.

Company-level read

Ticker impact

$NUWEBearishMedium confidence
Context

Q3 2026 GAAP EPS of -$5.81 and revenue of $2.21M were disclosed for the first time.

Expected impact

likely pressure as the market prices in the weak earnings

Evidence & confidence

Micro‑cap earnings surprise with negative EPS and stagnant sales typically triggers sell‑side activity.

Market effects

Minimal impact on the broader medical device sector.

Limited to U.S. micro‑cap investors.

Low

Counterpoint

If the company can turn the slight sequential sales growth into a turnaround, the dip may be overblown.

Key entities

  • Nuwellis Inc.

    Medical device manufacturer reporting Q3 2026 results.

Related articles

$NUWEMed

Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in…

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss Console unit sales increased 88% year-to-date versus pri

$NUWEHighAI 8/10

Nuwellis submits FDA application for pediatric Aquadex expansion

Nuwellis (NASDAQ: NUWE) submitted a 510(k) application to the FDA to expand the use of its Aquadex SmartFlow System to pediatric patients weighing 5 kg and above, currently cleared for 20 kg and above. The submission includes clinical data from the ULTRA-Peds Registry and aims to provide treatment options for fluid overload in smaller children. The company's CEO and a medical director commented on the strategic importance and clinical benefits of the expansion.

$NUWEMed

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 13, 2026 Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin Recent capital raise and warrant exercises extend cash runway through second quarter

$NUWEMed

Nuwellis Slumps on Share Sale

Nuwellis (NASDAQ: NUWE) entered a definitive securities purchase agreement for a registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds of about $3.1 million from warrant exercises tied to its June 2026 offering. In a concurrent private placement, investors receive warrants for up to 1,310,890 shares at $2.59, exercisable immediately, expiring in five years. Closing expected around Aug. 3, 2026.

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.